SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ZABRISKIE JOHN L

(Last)

(First)

(Middle)

207 JUNIPER COURT

(Street)

BASALT

81621

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/27/2009

3. Issuer Name and Ticker or Trading Symbol
ARCA biopharma, Inc. [ ABIO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	29,180	I	See Footnote⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	⁽²⁾	08/03/2015	Common Stock	3,887	$0.6	D
Option to Purchase Common Stock	⁽³⁾	08/03/2016	Common Stock	5,694	$0.9	D
Option to Purchase Common Stock	⁽⁴⁾	02/02/2017	Common Stock	4,174	$1.68	D
Option to Purchase Common Stock	⁽⁵⁾	05/02/2018	Common Stock	4,174	$1.86	D
Option to Purchase Common Stock	⁽⁶⁾	01/22/2019	Commpn Stock	1,786	$5.57	D

Explanation of Responses:

1. These shares are owned directly by Lansing Brown Investments, LLC. Dr. Zabriskie, one of ARCA's current directors, is the President of Lansing Brown Investments, LLC. Dr. Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them

2. The options vested as to 971 shares on May 4, 2006; and continue to vest by 242 shares at the end of each quarter thereafter.

3. The options vested as to 1,423 shares on August 3, 2007; and continue to vest by 355 shares at the end of each quarter thereafter.

4. The options vested as to 1,043 shares on February 2, 2008; and continue to vest by 260 shares at the end of each quarter thereafter.

5. The options vest as to 1,043 shares at the end of each quarter following grant date.

6. The options are immediately exercisable.

Remarks:

	Patrick Wheeler, attorney in fact	02/05/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.